However, its not without potential side effects such as mild gastrointestinal discomfort or nausea
You might wonder if the injection is doing anything
The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible beneficiaries weight-loss access to Wegovy at $50/month outside the Part D benefit
Learn more (As always, timelines can shift with FDA review and manufacturing readiness.) What the new mechanism is: The mechanism is still GLP-1 receptor activation, but the innovation is the delivery technology (oral small molecule) a major change in how GLP-1 therapy may be taken
Nishimura Y, Kanda Y, Sone H, Aoyama H